Factors that influence rheumatologists' decisions to escalate care in rheumatoid arthritis: Results from a choice-based conjoint analysis

Arthritis Care and Research

Volumn 62, Issue 6, 2010, Pages 842-847

  Kievit, Wietske ^a   Van Hulst, Laura ^a   Van Riel, Piet ^a   Fraenkel, Liana ^b,c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; ARTICLE; BAYES THEOREM; CLINICAL DECISION MAKING; CLINICAL PRACTICE; COMPUTER PROGRAM; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE DURATION; HEALTH CARE SURVEY; PATIENT CARE; PRACTICE GUIDELINE; RHEUMATOID ARTHRITIS; SCORING SYSTEM;

ADOLESCENT; ADULT; AGE FACTORS; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; CHOICE BEHAVIOR; DATA COLLECTION; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT CARE; PHYSICIAN-PATIENT RELATIONS; PHYSICIANS; RHEUMATOLOGY; YOUNG ADULT;

EID: 77953111701     PISSN: 21514658     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/acr.20123     Document Type: Article

References (29)

1. Fransen J, Moens HB, Speyer I, van Riel PL. Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial. Ann Rheum Dis 2005;64:1294-1298 (Pubitemid 41206245)
2. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381-3390
3. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263-269 (Pubitemid 38942816)
4. Makinen H, Kautiainen H, Hannonen P, Mottonen T, Leirisalo-Repo M, Laasonen L, et al. Sustained remission and reduced radiographic progression with combination disease modifying antirheumatic drugs in early rheumatoid arthritis. J Rheumatol 2007;34:316-321 (Pubitemid 46255748)
5. Verstappen SM, Jacobs JW, van der Veen MJ, Heurkens AH, Schenk Y, ter Borg EJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007;66:1443-1449 (Pubitemid 350032650)
6. Choy EH, Khoshaba B, Cooper D, MacGregor A, Scott DL. Development and validation of a patient-based disease activity score in rheumatoid arthritis that can be used in clinical trials and routine practice. Arthritis Rheum 2008;59:192-199
7. Pincus T, Sokka T. Quantitative measures for assessing rheumatoid arthritis in clinical trials and clinical care. Best Pract Res Clin Rheumatol 2003;17:753-781 (Pubitemid 37045307)
8. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight - joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-48
9. Schmajuk G, Schneeweiss S, Katz JN, Weinblatt ME, Setoguchi S, Avorn J, et al. Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal. Arthritis Rheum 2007;57:928-934 (Pubitemid 47237318)
10. Wolfe F, Michaud K. Resistance to changing therapy: discordance between RA activity and patients' treatment choices [abstract]. Arthritis Rheum 2006;54 Suppl:S425-6. (Pubitemid 47173560)
11. Creemers M, Fransen J, Welsing P, Kievit W, van Riel P. Assessment of the DAS28 in rheumatoid arthritis patients in daily clinical practice: is monitoring enough to reach low disease activity? [abstract]. Arthritis Rheum 2005;52 Suppl: S116-7.
12. Ryan M, Gerard K, Amya-Amaya M. Using discrete choice experiments to value health and health care. 1st ed. Houten (The Netherlands): Springer; 2008.
13. Ryan M, Farrar S. Using conjoint analysis to elicit preferences for health care. BMJ 2000;320:1530-1533 (Pubitemid 30330316)
14. Fraenkel L, Rabidou N, Dhar R. Are rheumatologists' treatment decisions influenced by patients' age? Rheumatology (Oxford) 2006;45:1555-1557
15. Howell J. Sawtooth Software research paper series: CBC/HB for beginners. 2009. URL: http://www.sawtoothsoftware.com/ download/techpap/CBCHBbeginners.pdf.
16. Orme B. Sawtooth Software research paper series. Hierarchical Bayes: why all the attention? 2000. URL: http://www.saw toothsoftware.com/download/techpap/ hbwhy.pdf.
17. Sawtooth Software. Sawtooth Software research paper series: the CBC/HB system for hierarchical Bayes estimation version 5.0 technical paper. 2009. URL: http://www.sawtoothsoft ware.com/download/techpap/hbtech.pdf.
18. Radovits BJ, Fransen J, Eijsbouts A, van Riel P, Laan RF. Missed opportunities in the treatment of elderly patients with rheumatoid arthritis. Rheumatology (Oxford) 2009;48:906-910
19. Radovits BJ, Kievit W, Fransen J, van der Laar MA, Jansen TL, van Riel PL, et al. Influence of age on the outcome of anti- TNFα therapy in rheumatoid arthritis. Ann Rheum Dis 2009; 68:1470-1473
20. Bathon JM, Fleischmann RM, van der Heijde D, Tesser JR, Peloso PM, Chon Y, et al. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. J Rheumatol 2006;33:234-243 (Pubitemid 43209297)
21. Schiff MH, Yu EB, Weinblatt ME, Moreland LW, Genovese MC, White B, et al. Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies. Drugs Aging 2006;23:167-178
22. Genevay S, Finckh A, Ciurea A, Chamot AM, Kyburz D, Gabay C, for the Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis. Tolerance and effectiveness of anti-tumor necrosis factor α therapies in elderly patients with rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2007;57:679-685
23. Fleischmann R, Baumgartner SW, Weisman MH, Liu T, White B, Peloso P. Long term safety of etanercept in elderly subjects with rheumatic diseases. Ann Rheum Dis 2006;65:379-384 (Pubitemid 43268229)
24. Welsing PM, van Gestel AM, Swinkels HL, Kiemeney LA, van Riel PL. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 2001;44:2009-2017
25. Welsing PM, Landewe RB, van Riel PL, Boers M, van Gestel AM, van der Linden S, et al. The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis Rheum 2004; 50:2082-2093 (Pubitemid 38924385)
26. Harrington JT. The uses of disease activity scoring and the physician global assessment of disease activity for managing rheumatoid arthritis in rheumatology practice. J Rheumatol 2009;36:925-929
27. Kievit W, Welsing PM, Adang EM, Eijsbouts AM, Krabbe PF, van Riel PL. Comment on the use of self-reporting instruments to assess patients with rheumatoid arthritis: the longitudinal association between the DAS28 and the VAS general health. Arthritis Rheum 2006;55:745-750
28. Wolfe F, Michaud K. Proposed metrics for the determination of rheumatoid arthritis outcome and treatment success and failure. J Rheumatol 2009;36:27-33.
29. Yazici Y, Krasnokutsky S, Barnes JP, Hines PL, Wang J, Rosenblatt L. Changing patterns of tumor necrosis factor inhibitor use in 9074 patients with rheumatoid arthritis. J Rheumatol 2009;36:907-913